ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
Eligibility criteria
Qualifiers
The participant has a histologically or cytologically confirmed diagnosis of colorectal cancer.
Confirmation of non-MSI-H/pMMR status.
Tumor that is measurable as per RECIST v1.1 and biopsy able, defined as lesion/tumor that can be biopsied without undue risk.
Age ≥ 18 years.
Disqualifiers
Pregnancy.
Participants with concurrent or recent (less than 1 year before consent) malignancies that have the potential to interfere with the study safety and/or endpoint assessments will be excluded.
Participants for whom there is an intent to proceed to curative therapy (i.e., resection) will be excluded.
Participants who have undergone treatment with both oxaliplatin and irinotecan in the metastatic setting will be excluded. Treatment with oxaliplatin in the adjuvant setting with relapse within 6 months will be counted as treatment in the metastatic setting for the purpose of this criterium.
Trial design
Treatments tested in this trial
- SOC (Standard of care)
- Bevacizumab
- Cetuximab
- Panitumumab
- FOLFIRI
- FOLFOX
- Encorafenib
- Adagrasib
- Trifluridine/tipiracil (TAS-102)
- Trastuzumab deruxtecan
- Tucatinib
- Sotorasib
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov